Connect with us

Australia

Zelda Therapeutics and Ilera Therapeutics plan merger to “disrupt medicinal cannabis markets”

Zelda Therapeutics Ltd (ASX:ZLD) (FRA:G1G) (OTCMKTS:ZLDAF) is expected to increase its market capitalisation and reach on merging with fellow international medicinal cannabis company Ilera Therapeutics LLC to become Zelira Therapeutics.

Subject to approval from Zelda shareholders and all conditions of sale being met, Zelda is proposing to acquire 100% of Ilera through an all-scrip transaction.

Zelda reported that the merger would bring together a “leading pipeline of clinical candidates, revenue-generating medicines, and a combined strategy to disrupt global medicinal cannabis and pharmaceutical markets”.

Industry disruption is a goal in many industries, including medicinal cannabis, which is a fast-growing pharmaceutical market.

“Transformational opportunity”
Zelda's executive chairman Harry Karelis said, “This is a transformational opportunity for both companies.

“The merger will create one of the worlds leading medicinal cannabis companies with a rich pipeline of clinicall..

Zelda Therapeutics Ltd (ASX:ZLD) (FRA:G1G) (OTCMKTS:ZLDAF) is expected to increase its market capitalisation and reach on merging with fellow international medicinal cannabis company Ilera Therapeutics LLC to become Zelira Therapeutics.

Subject to approval from Zelda shareholders and all conditions of sale being met, Zelda is proposing to acquire 100% of Ilera through an all-scrip transaction.

Zelda reported that the merger would bring together a “leading pipeline of clinical candidates, revenue-generating medicines, and a combined strategy to disrupt global medicinal cannabis and pharmaceutical markets”.

Industry disruption is a goal in many industries, including medicinal cannabis, which is a fast-growing pharmaceutical market.

"Transformational opportunity"

Zelda's executive chairman Harry Karelis said, “This is a transformational opportunity for both companies.

“The merger will create one of the worlds leading medicinal cannabis companies with a rich pipeline of clinically validated products under development and unique access to the worlds largest and fastest-growing cannabis markets.”

Zelda is backed by key figures in the Australian biotechnology industry, including co-founders and directors Mara Gordon, Dr Stewart Washer and Karelis, and is jointly led by Karelis and managing director Dr Richard Hopkins.

The new Zelira will target international markets with its operations in Australia and the USA so it can access large, profitable and fast-growing medicinal cannabis market segments.

Zelira aims to bank receipts from HOPE brand Ilera cannabis formulations recently launched in Pennsylvania.

Revenue HOPEs

Ilera Therapeutics has rights to HOPE in other markets outside of the US state and has plans to market this and other products across the US and in global markets.

A Zelira dermatology subsidiary would also produce dermatology products created by board-certified cosmetic dermatologist Dr Karyn Grossman for the retail and cannabis regulated markets.

Zelda said its proposed merger would capture synergies and predicted it would help improve shareholder value for investors in both companies.

Karelis highlighted the potential for the merger to allow Zelda to speed up its plans to differentiate itself through “robust” clinical trials and be at the forefront of the medicinal cannabis sector worldwide.

He said, “The merger will enable the combined company to accelerate plans to disrupt the medicinal cannabis and pharmaceutical markets globally.”

An “excellent fit”

Ilera chairman Osagie Imasogie welcomed the merger, saying “Ilera Therapeutics and Zelda are an excellent and natural fit, given our respective clinical development straRead More – Source/a>

Continue Reading

Australia

Galileo Mining to present emerging Fraser Range story during Share Café Nickels New Wave Webinar today

Galileo Mining Ltd (ASX:GAL) managing director Brad Underwood will present the company's emerging Fraser Range nickel story at Share Café Nickels New Wave Webinar today at 12 noon AWST (2pm AEST).

Underwood will discuss the companys exploration programs underway at the Fraser Range Joint Venture (JV) Project with prominent regional player Creasy Group in Western Australia.

In March, the company identified nickel prospective rocks beneath shallow cover at the project.

The drilling results, combined with magnetic data showed three intrusions which have been named Think Big, Backwood and Green Moon.

These intrusions have the potential to host magmatic nickel mineralisation under shallow cover rock ranging from 17 metres to 92 metres below surface.

Nickel companies to be showcased[hhmc]
The free webinar today can be viewed live through Zoom over the internet and will provide viewers with the opportunity to hear from and engage with a range of emerging ASX-listed nickel exploratio..

Galileo Mining Ltd (ASX:GAL) managing director Brad Underwood will present the company's emerging Fraser Range nickel story at Share Café Nickels New Wave Webinar today at 12 noon AWST (2pm AEST).

Underwood will discuss the companys exploration programs underway at the Fraser Range Joint Venture (JV) Project with prominent regional player Creasy Group in Western Australia.

In March, the company identified nickel prospective rocks beneath shallow cover at the project.

The drilling results, combined with magnetic data showed three intrusions which have been named Think Big, Backwood and Green Moon.

These intrusions have the potential to host magmatic nickel mineralisation under shallow cover rock ranging from 17 metres to 92 metres below surface.

Nickel companies to be showcased


The free webinar today can be viewed live through Zoom over the internet and will provide viewers with the opportunity to hear from and engage with a range of emerging ASX-listed nickel exploration companies.

It will comprise 15-minute presentations plus a Q and A session.

Legend Mining Ltds (ASX:LEG) managing directoRead More – Source

Continue Reading

Australia

Musgrave Minerals shines after hitting 12 metres at 112.9 g/t gold near-surface at Starlight

Musgrave Minerals Ltd (ASX:MGV) surged to a record high after hitting 12 metres at 112.9 g/t gold near-surface in reverse circulation (RC) drilling at Starlight discovery within the flagship Cue Gold Project in Western Australia.

This bonanza-grade intersection from 36 metres included 6 metres at 143 g/t from 42 metres and the company is also buoyed by other high-grade results returned from the first 12 RC holes of the current campaign.

Shares have jumped more than 87% on the previous close to a new all-time high of 29 cents on strong early volume of more than 24 million.

Open-pit potential enhanced[hhmc]
Managing director Rob Waugh said: “This is a great start to the program and confirms the current model extending the mineralisation both up-dip where it approaches the surface and down-dip where it remains open.

“The bonanza high-grade, near-surface mineralisation will enhance the open-cut development potential of the deposit while the deeper mineralisation will enhance the underg..

Musgrave Minerals Ltd (ASX:MGV) surged to a record high after hitting 12 metres at 112.9 g/t gold near-surface in reverse circulation (RC) drilling at Starlight discovery within the flagship Cue Gold Project in Western Australia.

This bonanza-grade intersection from 36 metres included 6 metres at 143 g/t from 42 metres and the company is also buoyed by other high-grade results returned from the first 12 RC holes of the current campaign.

Shares have jumped more than 87% on the previous close to a new all-time high of 29 cents on strong early volume of more than 24 million.

Open-pit potential enhanced


Managing director Rob Waugh said: “This is a great start to the program and confirms the current model extending the mineralisation both up-dip where it approaches the surface and down-dip where it remains open.

“The bonanza high-grade, near-surface mineralisation will enhance the open-cut development potential of the deposit while the deeper mineralisation will enhance the underground potential.”

The RC drilling program at Starlight link-lode within the Break of Day deposit, which is now 60% complete, consists of more than 36 holes for around 7,000 metres and all intersections returned sit outside the current 199,000-ounce resource.

High-grades


Other strong results:

  • 48 metres at 4.4 g/t from 30 metres, including 4 metres at 41.8 g/t from 30 metres and 2 metres at 13.5 g/t from 76 metres;
  • 7 metres at 13.7 g/t from 114 metres including 4 metres at 22.9 g/t from 116 metres;
  • 6 metres at 5.7 g/t from 81 metres; and
  • 6 metres at 5.2 g/t from 176 metres.

All 6-metre composite samples above 0.1 g/t gold will be re-submitted for individual 1-metre sample analysis.

Ongoing exploration


Follow-up drilling on the new Starlight link-lode at Break of Day is underway, with additional assays expected within the next two weeks.

A diamond drillinRead More – Source

Continue Reading

Australia

Medlab Clinical receives first three batches of NanaBis™ from Tasmanian Alkaloids

Medlab Clinical Ltd (ASX:MDC) has received the first shipment of NanaBis, the company's patented cannabis-based medicine, from Tasmanian Alkaloids Pty Ltd (TASALK).

In line with a commercial agreement executed in January, NanaBis production and analytical services have been transferred to TASALK.

This allows for manufacturing to be ramped up, increases overall product quality and supports a stronger manufacturing compliance for the Australian Therapeutic Goods Administration, US Food and Drug Administration and the European Medicines Agency.

“Continues to grow”[hhmc]
Medlab chief executive officer Dr Sean Hall said: “With the recent launch of the Observational Study and successful completion of the Phase 2 Advanced Cancer Pain Trial at Royal North Shore Hospital, demand for NanaBis continues to grow.

“Being able to partner with TASALK is very exciting and allows Medlab to increase production capacities drastically over the short-term and therefore to meet increased demand.”

I..

Medlab Clinical Ltd (ASX:MDC) has received the first shipment of NanaBis™, the company's patented cannabis-based medicine, from Tasmanian Alkaloids Pty Ltd (TASALK).

In line with a commercial agreement executed in January, NanaBis™ production and analytical services have been transferred to TASALK.

This allows for manufacturing to be ramped up, increases overall product quality and supports a stronger manufacturing compliance for the Australian Therapeutic Goods Administration, US Food and Drug Administration and the European Medicines Agency.

"Continues to grow"


Medlab chief executive officer Dr Sean Hall said: “With the recent launch of the Observational Study and successful completion of the Phase 2 Advanced Cancer Pain Trial at Royal North Shore Hospital, demand for NanaBis™ continues to grow.

“Being able to partner with TASALK is very exciting and allows Medlab to increase production capacities drastically over the short-term and therefore to meet increased demand.”

Increased demand


The company reported that March quarterly revenue was achieved for NanaBis™ with aRead More – Source

Continue Reading

Trending